Skip to content

RadNet影像中心

US · RDNT #2019 按市值排名 上市于 1970
68.80 -1.61 -2.29%
实时 - 追踪5344个代码 - 心跳于537秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 5.04 处于历史正常水平 第55百分位
5年平均 4.89 · 在Diagnostics & Research中排名第23/40
市盈率 -269.92 低于历史水平 第25百分位
5年平均 18.04 · 前瞻 127.90
市销率 2.43 高于历史水平 第69百分位
5年平均 1.87 · 前瞻 2.10 · 在Diagnostics & Research中排名第13/43

同业对比 Diagnostics & Research

公司 市值 市盈率(TTM) 市净率 股息率
RadNet影像中心 (RDNT) 5.41B -264.62 4.94 0.00%
Thermo Fisher Scientific (TMO) 255.13B 37.14 4.84 0.26%
Danaher (DHR) 161.01B 40.68 3.06 0.63%
Natera (NTRA) 56.71B -291.44 31.13 0.00%
Agilent Technologies (A) 48.77B 34.12 6.62 0.59%
IDEXX Laboratories Inc (IDXX) 44.15B 39.38 27.38 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值80.04 经济护城河Narrow 不确定性High

当前股价低于晨星合理价值估算16.3%。

合理价值

RadNet Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $80.04 per share; however, caution is warranted due to this estimate's high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's balance sheet bolsters our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of 4.7, which sits in the bottom 30% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.9%, a core component of profitability, ranks in the bottom 40% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

经济护城河

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

RadNet影像中心 讨论区 0 条评论

发表评论